Nivolumab + Ipilimumab
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Merkel Cell Carcinoma
Conditions
Merkel Cell Carcinoma, Skin Cancer
Trial Timeline
Mar 14, 2017 → Sep 19, 2026
NCT ID
NCT03071406About Nivolumab + Ipilimumab
Nivolumab + Ipilimumab is a phase 2 stage product being developed by Bristol Myers Squibb for Merkel Cell Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT03071406. Target conditions include Merkel Cell Carcinoma, Skin Cancer.
What happened to similar drugs?
0 of 1 similar drugs in Merkel Cell Carcinoma were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02186249 | Pre-clinical | Completed |
| NCT07024862 | Pre-clinical | Active |
| NCT06487156 | Pre-clinical | Active |
| NCT05219435 | Phase 2 | Active |
| NCT05302921 | Phase 2 | Completed |
| NCT05088889 | Phase 1 | UNKNOWN |
| NCT04966676 | Phase 2 | Terminated |
| NCT05215470 | Phase 2 | Active |
| NCT04465643 | Phase 1 | Completed |
| NCT04938232 | Phase 2 | Active |
| NCT04495010 | Phase 2 | Withdrawn |
| NCT04513522 | Approved | Completed |
| NCT04434560 | Phase 2 | Terminated |
| NCT04575922 | Phase 2 | UNKNOWN |
| NCT04340193 | Phase 3 | Completed |
| NCT04088500 | Phase 2 | Terminated |
| NCT04361162 | Phase 2 | Active |
| NCT03873402 | Phase 3 | Active |
| NCT03461952 | Phase 2 | Terminated |
| NCT03789110 | Phase 2 | Active |
Competing Products
20 competing products in Merkel Cell Carcinoma